Company news
Greenwich Lifesciences, Inc. (NASDAQ:GLSI) news
Greenwich Lifesciences, Inc. news releases on 6ix. Latest, Jun 26, 2024: Greenwich LifeSciences Set to Join Russell 2000 Index Again
Press releases — page 2
Greenwich LifeSciences Set to Join Russell 2000 Index Again
June 25, 2024
Greenwich LifeSciences Announces $2.5 Million Private Placement
June 13, 2024
Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025
March 12, 2024
Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe
March 11, 2024
Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries
February 26, 2024
Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators
February 21, 2024
Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01
February 13, 2024
Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2024
November 20, 2023
Greenwich LifeSciences Provides Year End Update
December 28, 2022
Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2023
November 30, 2022
Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical Trial
August 10, 2022
Greenwich LifeSciences Provides Updates on Flamingo-01 Phase III Clinical Trial
August 2, 2022
Greenwich LifeSciences Provides Financing Strategy & Corporate Update
July 27, 2022
Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed
July 11, 2022
Greenwich LifeSciences Announces Suspension of Share Repurchase Program
July 10, 2022
Greenwich LifeSciences to Resume Stock Repurchase Program
May 22, 2022
Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial & ASCO Meeting
May 22, 2022
Greenwich LifeSciences to Participate in Upcoming Jefferies, Wainwright, ASCO and BIO International Conferences
April 19, 2022
Greenwich LifeSciences Presents Phase IIb Data, Published at AACR 2022, Further Supporting the Role of GP2 in Preventing Metastatic Breast Cancer
April 18, 2022
Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial, Patent Filings, & AACR Meeting
March 2, 2022
Greenwich LifeSciences to Present at 2022 BIO CEO & Investor Conference
February 2, 2022
Greenwich LifeSciences Provides Update on Upcoming Phase III Clinical Trial, FLAMINGO-01
January 31, 2022
Greenwich LifeSciences to Implement Stock Repurchase Program for up to $10 Million & to Extend Lock-up of Insiders for an Additional 1 Year
January 23, 2022
Greenwich LifeSciences CEO Participates in TD Ameritrade Interview to Discuss 2021 SABCS Poster
December 14, 2021
Greenwich LifeSciences Announces Presentation of 5 Year Data for GP2 Phase IIb Clinical Trial, Revealing Potential For New T Cell Platform Technology
December 8, 2021
Greenwich LifeSciences to Participate in Multiple Interviews and Conferences
December 7, 2021
Greenwich LifeSciences Expands Role of Industry Expert Dr. F. Joseph Daugherty to Include Medical Monitor for its Upcoming Phase III Clinical Trial
December 6, 2021
Greenwich LifeSciences Announces Commencement of the First Commercial Line Filling of GP2
December 5, 2021
Greenwich LifeSciences CEO Interview to Air on Bloomberg U.S. on the RedChip Money Report
November 17, 2021
Greenwich LifeSciences to Participate in Jefferies’ 12th Annual London Healthcare Conference
November 16, 2021
Greenwich LifeSciences Announces Acceptance of Two Posters at Upcoming 2021 SABCS Breast Cancer Conference
November 10, 2021
Greenwich LifeSciences Provides Clinical Update on Upcoming Phase III Clinical Trial, FLAMINGO-01
November 9, 2021
Greenwich LifeSciences Provides Updated Corporate Presentation and Webcasts
November 8, 2021
Greenwich LifeSciences to Partner with Susan G. Komen Race for the Cure Houston
September 27, 2021
Greenwich LifeSciences to Present at the Benzinga Healthcare Small Cap Conference
September 26, 2021
Greenwich LifeSciences to Present at the Cantor Global Healthcare Conference
September 22, 2021
Greenwich LifeSciences to Present at H.C. Wainwright 23rd Annual Global Investment Conference
September 12, 2021
Greenwich LifeSciences Provides Updates on Recent and Upcoming Developments
September 8, 2021
Greenwich LifeSciences to Participate in Citi’s 16th Annual Biopharma Virtual Conference
September 6, 2021
Greenwich LifeSciences Set to Join Russell 2000® Index
June 7, 2021
Greenwich LifeSciences Publishes Additional Positive Safety Data from GP2 Phase IIb Trial at ASCO 2021, Confirming that GP2 Treatment to Prevent Metastatic Breast Cancer Recurrence is Well Tolerated
June 6, 2021
Greenwich LifeSciences Hires Industry Expert Dr. Christine Fischette to Lead Business Development & Advise on Commercialization
April 18, 2021
Greenwich LifeSciences Announces Update of GP2 Phase III Clinical Trial Design at the 2021 AACR Annual Meeting
April 13, 2021
REPEAT/Greenwich LifeSciences Presents Phase IIb Poster, Published April 10th at 2021 AACR Annual Meeting, Showing GP2 Immune Response Peaked at 6 Months, Resulting in 100% Disease Free Survival from Recurring Breast Cancer
April 11, 2021
Greenwich LifeSciences Presents Immune Response Phase IIb Poster, Published Today at AACR 2021, Showing Peak Immunity after 6 Months of GP2 Treatment, Resulting in 100% Disease Free Survival from Recurring Breast Cancer
April 9, 2021
Greenwich LifeSciences Reports Robust Immune Response Phase IIb Data Supporting GP2 Clinical Outcome of 0% Metastatic Breast Cancer Recurrences Over 5 Years of Follow-up
April 8, 2021
Greenwich LifeSciences CEO to Participate on Cancer Panel and to Present at Benzinga Biotech Conference
March 22, 2021
Greenwich LifeSciences Updates 2021 Timeline & Announces Two Upcoming Presentations at the American Association for Cancer Research Annual Meeting
March 10, 2021
Greenwich LifeSciences CEO to be Interviewed Live on Benzinga’s Power Hour
March 9, 2021
Greenwich LifeSciences Hires Industry Expert, Dr. Jaye Thompson, to Manage Phase III Clinical Trial for Recurring Breast Cancer
March 7, 2021